Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simeprevir, Sofosbuvir, and Ribavirin for HCV Genotype 1 with Early Decompensated Cirrhosis
NCT02455167Phase 3Terminated
- Sponsor
- University of Colorado Denver
- Start
- May 2015
- Primary completion
- Jul 2016
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of simeprevir in hepatitis C (HCV), sponsored by University of Colorado Denver. Started May 2015; status: terminated.
02
Drugs
simeprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02455167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02455167.